Hot Biotech Stocks in the News – AMGN, ARNA, CELG, VVUS
Houston, TX – January 28, 2013 — (Net PR News) – AnotherWinningTrade.com offers its daily alerts and market content newsletter to investors looking for the best information available! AnotherWinningTrade.com provides its subscribers with useful, timely information and exclusive alerts on penny stocks, mid cap stocks and large cap stocks with the potential to deliver gains of 100%-200% or more. We have the top alerts in the industry. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.
Today’s Stocks in focus are: AMGN, ARNA, CELG, VVUS
Amgen, Inc. (NASDAQ:AMGN) announced its results from the evaluation study of Pegfilgrastim and Anti-VEGF. During Phase 3 of its trial, the company evaluated Neulasta® (pegfilgrastim) in 845 patients getting bevacizumab and FOLFOX or FOLFIRI for the first stage of treatment of locally-advanced or metastatic colorectal cancer. FOLFOX and FOLFIRI are frequently used chemotherapy regimens for colorectal cancer.
Amgen, Inc. (NASDAQ:AMGN) percentage change surged 0.97% to close at $83.42 with the total traded volume of 7.24 million shares, as compared to average volume of 5.10 million shares.
Get A Free Report And Detailed Analysis On AMGN CLICK HERE To Read
AMGN’s total market capitalization is $63.07 billion along with 756.00 million shares outstanding. Its beta value stands at 0.40 points and its earning per shares remained $5.52. The Company’s lowest price during last trade was $82.09 while its highest price remained 83.43 for the day.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported an upsurge of 0.46% after opening at the price of $8.74. Its closing price for the day was $8.71.
Arena Pharmaceuticals Company’s earning per share is $-0.53 while its beta value stands at 0.24 times. The Company’s current market capitalization stands at $1.89 billion, along with 217.29 million shares. ARNA’s total trading volume for the day was 5.35 million shares, versus its average volume of 11.48 million shares.
Is ARNA A Solid Investment At These Levels? Find Out Exactly Where ARNA Is Headed With This TREND ANALYSIS REPORT
If we look at the previous 5 day’s performance of the stock, it remained decreasing with the loss of -9.83%and, in its last one month’s trade it declined -1.58%.
Celgene Corporation (NASDAQ:CELG) reported its fiscal fourth quarter results. Its net-product sales remained $1,416 million for the quarter, an advancement of 14% from the previous year. Adjusted diluted earnings per share rose 26%, from $1.05 to $1.32.
Celgene Corporation percentage change increased 2.33% to close at $99.76 with the total traded volume of 5.18 million shares, as compared to average volume of 4.06 million shares.
How Should Investors React To CELG Now? Find Out In This TREND ANALYSIS REPORT
CELG’s shares were trading within the range of $96.30-$99.90, while its opening price was $96.42. Its market capitalization is $42.20 billion and EPS was $3.30. If we look at its previous three months trade, it gained 32.66%, while in the last 5 day’s it remained up 1.6%.
Another Biotechnology company showing negative moment during previous trade, VIVUS, Inc. (NASDAQ:VVUS), reported the decrease of -4.55% and closed at $12.39 with the total traded volume of 4.98 million shares. The stock’s opening price was $12.99.
The 52-week price range of the stock remained $9.86 – $31.21, while during last trade its minimum price was $12.30 and it gained its highest price of $13.02.
How Should Investors Trade VVUS Now? Don’t Trade VVUS Until You Read This TREND ANALYSIS REPORT
The company has the total of 100.59 million outstanding shares and its total market capitalization is $1.25 billion. The Company’s last 5 days shows a downtrend with the drop of -10.8%.
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.